References
- Goldstein A. “The Interaction of Drugs and Plasma Proteins,”. Pharmacol. Rev. 1949; 1: 102–165
- Meyer M. C., Guttman D. E. “The Binding of Drugs by Plasma Proteins,”. J. Pharm. Sci. 1968; 57: 895–918
- Transport Function of Plasma Proteins, P. Desgrez, P. M. DeTraverse. Elsevier, New York 1966
- Settle W., Hegeman S., Featherstone R. M. “The Nature of Drug-Protein Interaction,”. Concepts in Biochemical Pharmacology, B. B. Brodie, J. R. Gillette. Springer, New York 1971; 175–186, Chap. 8, Part 1
- Chignell C. F. “Physical Methods for Studying Drug-Protein Binding,”. Concepts in Biochemical Pharmacology, B. B. Brodie, J. R. Gillette. Springer, New York 1971; 187–212, Chap. 9, Part 1
- Keen P. “Effect of Binding to Plasma Proteins on the Distribution, Activity and Elimination of Drugs,”. Concepts in Biochemical Pharmacology, B. B. Brodie, J. R. Gillette. Springer, New York 1971; 213–233, Part 1, Chap. 10
- Solomon H. M. “Competition between Drugs and Normal Substrates for Plasma and Tissue Binding Sites,”. Concepts in Biochemical Pharmacology, B. B. Brodie, J. R. Gillette. Springer, New York 1971; 234–239, Part 1, Chap. 11
- Davison C. “Protein Binding,”. Fundamentals of Drug Metabolism and Drug Disposition, B. M. LaDu, H. G. Mandel, E. L. Way. Williams and Wilkins, Baltimore 1971; 63–75, Chap. 4
- Westphal U. F., Knoeful P. K. “Binding of Drugs,”. Absorption, Distribution, Transformation, and Excretion of Drugs, P. K. Knoeful. Thomas, Springfield, Illinois 1972; 56–76, Chap. 3
- Krasner J. “Drug-Protein Interaction,”. Pediatr. Clin. North Am. 1972; 19: 51–63
- Klotz I. M. “Protein Interactions with Small Molecules,”. ACC. Chem. Res., 7: 162–168
- Anton A. H., Solomon H. M. “Drug-Protein Binding.”. Ann. N. Y. Acad. Sci. 1973; 226
- Schultze H. E., Heremans J. F. Molecular Biology of Human Proteins, Vol. 1, Nature and Metabolism of Extracellular Proteins. Elsevier, New York 1966, Chap. 2, Section II
- Courtice F. C. “Lymph and Plasma Proteins: Barriers to Their Movement Throughout the Extracellular Fluid,”. Lymphology 1971; 4: 9–17
- Rothschild M. A., Bauman A., Yalow R. S., Berson S. A. “Tissue Distribution of I131 Labeled Human Serum Albumin Following Intravenous Administration,”. J. Clin. Invest. 1955; 34: 1354–1358
- Rothschild M. A., Oratz M., Schreiber S. S. “Albumin Metabolism,”. Gastroenterology 1973; 64: 324–337
- Beeken W. L., Volwiler W., Goldsworthy P. D., Garby L. E., Reynolds W. E., Stogsdill R., Stemler R. S. “Studies of I131 Albumin Catabolism and Distribution in Normal Young Male Adults,”. J. clin. Invest. 1962; 41: 1312–1333
- Takeda Y., Reeve E. B. “Studies of the Metabolism and Distribution of Albumin with Autologous I113 Albumin in Healthy Men.,”. J. Lab. Clin. Med. 1963; 61: 183–202
- Walker W. G., Ross R. S., Hammond D. S. “Study of the Relationship between Plasma Volume and Transcapillary Protein Exchange Using I131 Labeled Albumin and I125 Labeled Globulin,”. Circ. Res. 1960; 8: 1028–1040
- Cohen S., Freeman T., McFarlane A. S. “Metabolism of I131 Labeled Human Albumin,”. Clin. Sci. 1961; 20: 161–170
- Wilkinson P., Mendenhall C. L. “Serum Albumin Turnover in Normal Subjects and Patients with Cirrhosis Measured by I131 Labeled Human Albumin,”. Clin. Sci. 1963; 25: 281–292
- Dykes P. W. “The Rates of Distribution and Catabolism of Albumin in Normal Subjects and in Patients with Cirrhosis of the Liver,”. Clin. Sci. 1968; 34: 161–183
- Davies R. G. “Correlation and Regression Analysis,”. Computer Programming in Quantitative Biology. Academic, New York 1971; 181–215, Chap. 7
- Plantin L. O., Ahlinder S., Norberg R., Birke G. “The Distribution of Proteins between Intra and Extravascular Spaces in Health and Disease,”. Act a Med. Scand. 1971; 189: 309–314
- Casey A. E., Gilbert F. E., Copeland H., Downey E. L., Casey J. G. “Albumin, Alpha 1, 2, Beta and Gamma Globulin in Cancer and Other Diseases,”. South. Med. J. 1973; 66: 179–185
- Ablin R. J., Gonder M. J., Soanes W. A. “Serum Proteins in Prostatic Cancer I. Relationship Between Clinical Stage and Level,”. J. Urol. 1973; 110: 238–241
- Petermann M. L. “Alterations in Plasma Protein Patterns in Disease,”. The Plasma Proteins, Vol. 2, Biosynthesis, Metabolism, Alterations in Disease, F. W. Putman. Academic, New York 1960, Chapter 17
- Birke G., Liljedahl S. O., Plantin L. O., Wetterfors J. “Albumin Catabolism in Burns and Following Surgical Procedures,”. Acta Chir, Scandin. 1959–1960; 118: 353–366
- Casten D., Bodenhumer M., Burcham J. “A Study of Plasma Protein Variation in Surgical Procedure,”. Ann. Surg. 1943; 117: 52–73
- Mouridsen H. T. “Turnover of Human Serum Albumin Before and After Operation,”. Clin. Sci. 1967; 33: 345–354
- Birke G., Liljedahl S. O., Plantin L. O., Reizenstein P. “Studies of Burns IX. The Distribution and Losses through the Wound of I131 Albumin Measured by Whole-Body Counting,”. Acta Chir. Scand. 1968; 134: 27–36
- Gleichmann W., Backmann G. W., Dengler H. J., Dudeck J. “Effect of Hormonal Contraceptives and Pregnancy on Serum Protein Pattern,”. Eur. J. clin. Pharmacol. 1973; 5: 218–225
- Midler G. B., Alling E. L., Morton J. J. “Effect of Neoplastic and Allied Diseases on Concentration of Plasma Proteins,”. Cancer 1950; 3: 56–65
- Steinfeld J. L. “I131 Albumin Degradation in Patients with Neoplastic Diseases,”. Cancer 1960; 13: 974–984
- Rothschild M. A., Oratz M., Schreiber S. S. “Albumin Synthesis,”. N. EngL J. Med. 1972; 266: 748–157
- Kradjan W. A. “Hepatitis and Cirrhosis,”. J. Am. Pharm. Assoc. 1973; 13: 578–586
- Sunderman F. W. “Recent Advances in Clinical Interpretation of Electrophoretic Fractionations of the Serum Proteins,”. Serum Proteins and the Dysproteinemias, F. W. Sunderman, F. W. Sunderman, Jr. Lippincott, Philadelphia 1964; 323–345, Chap. 32
- Jensen H., Rossing N., Andersen S. B., Jarnum S. “Albumin Metabolism in the Nephrotic Syndrome in Adults,”. Clin. Sci. 1967; 33: 445–457
- D'Addabbo A., Pastore G., Muscoguiri A., Fonfani G., Damato V. “Protein Loss into the Sputum and Faeces of Patients with Chronic Bronchitis: Lung Clearance of 51Cr Labeled Human Serum Albumin,”. J. Nucl. Biol. Med. 1968; 12: 73–76
- Masson P. L., Heremans J. F., Prignot J. “Studies on the Proteins of Human Bronchial Secretion,”. Biochim. Biophys. Acta 1965; 111: 466–478
- Bonomo L., D'Addabbo A. “I131 Albumin Turnover and Loss of Proteins into the Sputum in Chronic Bronchitis,”. Clin. Chim. Acta 1964; 10: 214–222
- Strober W., Peter G., Schwartz R. H. “Albumin Metabolism in Cystic Fibrosis,”. Pediatrics 1969; 43: 416–426
- McPherson I. G. “Albumin Metabolism in Diabetes Mellitus,”. Clin. Chim. Acta 1973; 49: 261–275
- Dales L. G., Friedman G. D., Siegelaub A. B., Seltzer C. C. “Cigarette Smoking and Serum Chemistry Tests,”. J. Chronic Dis. 1974; 27: 293–307
- Cay E. A., Gilbert F. E., Gravice J. F., Downey E. L. “Low Urea-Nitrogen and Elevated Serum Albumin in Anxiety, Neuroses, and Psychoses,”. Ala. J. Med Sci. 1971; 8: 168–177
- Ecanow B., Gold B. H., Tunkunas P. “Serum Albumin and Urea During States of Anxiety and Depression”. J. Am. Med. Assoc. 1973; 226: 356
- Martin B. K. “Kinetics of Elimination of Drugs Possessing High Affinity for the Plasma Protein,”. Nature 1965; 207: 959–960
- Kruger-Thiemer E., Deller W., Bunger P. “Pharmacokinetic Models Regarding Protein Binding of Drugs,”. Antimicrob. Agents Chemother. 1965; 183–491
- Coffey J. J., Bullock F. J., Schoenemann P. T. “Numerical Solution of Nonlinear Pharmacokinetic Equations: Effects of Plasma Protein Binding on Drug Distribution and Elimination,”. J. Pham. Sci. 1971; 60: 1623–1628
- Coffey J. J. “Effects of Protein Binding of Drugs on Areas under Plasma Concentration-Time Curver,”. J. Pham. Sci. 1972; 61: 138–139
- Schoenemann P. T., Yesair D. W., Coffey J. J. “Pharmacokinetic Consequences of Plasma Protein Binding of Drugs,”. Ann. N. Y. Acad. Sci. 1973; 226: 162–171
- Martin B. K. “Potential Effects of the Plasma Proteins on Drug Distribution,”. Nature 1965; 207: 274–276
- Skrabal F., Arnot R. N., Joplin G. F. “Equations for the Prediction of Normal Values for Exchangeable Na+, Exchangeable K+, Extracellular Fluid Volume and Total Body Water,”. Br. Med. J. 1973; 2: 37–38
- Cook D. R., Galla S. J., Gualtiere W. S. “A Safer Method for Measuring Body Fluid Compartments in Patients,”. Anesthesiology 1965; 30: 660–662
- Wagner J. G. “Body Water Compartments and the Distribution of Drugs,”. Biopharmaceutics and Relevant Pharmacokinetics. Drug Intelligence Publications, Hamilton, Illinois 1971; 260–265, Chap. 33
- Haxhe J. J. “Body Composition and Electrolyte Studies,”. Radio-isotopes in Medical Diagnosis, E. H. Belcher, H. Vetter. Appleton-Century-Crofts, New York 1971; 258–297, Chap. 12
- Bischoff K. B., Dedrick R. L. “Thiopental Pharmacokinetics,”. J. Pharm. Sci. 1968; 57: 1346–1351
- Bischoff K. B., Dedrick R. L., Zaharko D. S., Longstreth J. A. “Methotrexate Pharmacokinetics,”. J. Pharm. Sci. 1971; 60: 1128–1133
- Dedrick R. L., Forrester D. D., Ho D. H. W. “In vitro-in vivo Correlation of Drug Metabolism-Deamination of 1-β-D-Arabinofuranosylcytosine,”. Biochem. Pharmacol. 1972; 21: 1–16
- Jusko W. J. “Factors Affecting the Pharmacokinetics of Some Psychoactive Drugs,”. Clinical Pharmacology of Psychoactive Drugs, E. M. Sellers. Alcoholism and Drug Addiction Research Foundation, Toronto 1975; 55–71
- Litwack G., Ketterer B., Arias I. M. “Ligandin: A Hepatic Protein Which Binds Steroids, Bilirubin, Carcinogens, and a Number of Exogenous Organic Anions,”. Nature 1971; 234: 466–467
- Fleishner G., Robbins J., Arias I. M. “Immunological Studies of Y Protein,”. J. Clin. Invest. 1972; 51: 677–684
- Sokoloff J., Berk R. N., Lang J. H., Lasser E. C. “The Role of the Y and Z Hepatic Proteins in the Excretion of Radiographic Contrast Materials,”. Radiology 1973; 106: 519–523
- Ariens E. J. “Modulation of Pharmacokinetics by Modification of the Various Factors Involved,”. Farmaco, Ed. Sci. 1969; 24: 3–102
- Allen L. M., Creaven P. J. “Binding of a New Antitumor Agent, Thalicorpine, to DNA,”. J. Pharm. Sci. 1974; 63: 474–475
- Zee-Cheng K. Y., Cheng C. C. “Common Receptor-Complement Features Among Some Antileukemic Compounds”. J. Pharm. Sci. 1970; 59: 1630
- Blois M. S., Taskovich L. “The Reversible Binding of Some Aromatic and Cyclic Compounds to Biopolymers in vitro,”. J. Invest. Dermatol. 1969; 53: 344–350
- Kurnick N. B., Radcliffe I. E. “Reaction between DNA and Quinacrine and Other Antimalarials,”. J. Lab. Clin. Med. 1962; 60: 669–688
- Bernstein H., Zvaifler N., Rubin M., Mansour A. M. “The Ocular Deposition of Chloroquine,”. Invest. Ophthalmol. 1963; 2: 384–392
- Potts A. “The Concentration of Phenothiazines in the Eye of Experimental Animals,”. Invest. Ophthalmol. 1962; 1: 522–530
- Patil P. N. “Cocaine-Binding by the Pigmented and the Non-Pigmented Iris and Its Relevance to the Mydriatic Effect,”. Invest. Ophthalmol. 1972; 11: 739–746
- Patil P. N., Shimada K., Feller D. R., Malspeis L. “Accumulation of (-)−14C- Ephedrine by the Pigmented and the Non-Pigmented Iris,”. J. Pharmacol. EXp. Ther. 1974; 188: 342–352
- Blois M. S. “The Binding Properties of Melanin: In vivo and in vitro,”. Pharmacology-and the Skin, Adv. Biol. Skin 1972; 12: 65–79, Chap. 6 in
- Weinstein L., IV. “The Tetracyclines: Chlortetracyline, Oxytetracycline, Tetracycline, and Demethylchortetracycline,”. The Pharmacological Basis of Therapeutics, 3rd ed., L. S. Goodman, A. Gilman. Macmillan, New York 1965; 1242–1259, Chap. 59
- Lukas D. S., DeMartino A. G. “Binding of Digitoxin and Some Related Cardenolides to Human Plasma Proteins,”. J. Clin. Invest. 1969; 48: 1041–1053
- Evered D. C. “The Binding of Digoxin by the Serum Proteins,”. Eur. J. Pharmacol. 1972; 18: 236–244
- Godfraind T., Lane M. “The Uptake of Cardiac Glycosides in Relation to Their Actions in Isolated Cardiac Muscle,”. Br. J. Pharmacol. 1972; 46: 488–497
- Gardner D., Kiino D. R., Swartz T. J., Butler V. P. “Effects of Digoxin-Specific Antibodies on Accumulation and Binding of Digoxin by Human Erythrocytes,”. J. Clin. Invest. 1973; 52: 182–183
- Thomas R. “Enzymes as Drug Receptors: Transport ATPase,”. Aust. J. Pharm. Sci., [N. S.] 1972; 1: 9–15
- Genazzani E., Santamaria R. “Interaction of Cardiac Glycosides with Serum Albumin and Contractile Proteins,”. Pharmacol. Res. Commun. 1969; 1: 249–257
- Doherty J. E., Perkins W. H., Flanigan W. J. “The Distribution and Concentration of Tritiated Digoxin in Human Tissues,”. Ann. Intern. Med. 1967; 66: 116–124
- Jusko W. J., Weintraub M. “Myocardial Distribution of Digoxin and Renal Function,”. Clin. Pharmacol. Ther. 1974; 16: 449–454
- Remy V. G., Klitt M., Weber E. “Concentration of Ethambutal in CSF Fluid in Man as a Function of the Non-Protein Bound Drug Fraction in Serum,”. Eur. J. Clin. Pharmacol. 1973; 6: 133–136
- Acred P., Brown D. M., Clark B. F., Mizen L. “The Distribution of Antibacterial Agents between Plasma and Lymph in the Dog”. Br. J. Pharmacol 1970; 39: 439
- Verwey W. F., William H. R. “Binding of Various Penicillins by Plasma and Peripheral Lymph Obtained from Dog,”. Antimicrob. Agents Chemother. 1962; 484–491
- Tan J. S., Trott A., Phair J. P., Watanakunakorn C. “A Method for Measurement of Antibiotics in Human Interstitial Fluid”. J. Infect. Dis. 1972; 126: 492
- Chisholm G. D., Waterworth P. M., Calnan J. S., Garrod L. P. “Concentration of Antibacterial Agents in Interstitial Tissue Fluid,”. Br. Med. J. 1973; 1: 569–573
- Barza M., Samuelson T., Weinstein L. “Penetration of Antibiotics into Fibrin Loci in vivo. II Comparison of 9 Antibiotics: Effect of Dose and Degree of Protein Binding”. J. Infect. Dis. 1974; 129: 66
- Kunin C. M. “Binding of Antibiotics to Tissue Homogenate,”. J. Infect. Dis. 1970; 121: 55–64
- Green J. P. “Binding of Some Biogenic Amines in Tissues,”. Adu. Pharmacol. 1962; 349–442
- Kuntzman R., Jacobson M., Tsai I., Burns J. J., Burchall J., Kock A. “Certain Aspects of Drug Binding to Non-Plasma Proteins as Illustrated by Studies with Cyclizine. Chlorcyclizine and Polymyxin B”. Ann. N. Y. Acad. Sci. 1973; 226
- Wagner J. G. “A New Generalized Non-Linear Pharmacokinetic Model and Its Implications,”. Biopharmaceutics and Relevant Pharmaco kinetics. Drug Intelligence Publications, Hamilton, Illinois 1971; 302–317, Chap. 40
- DiSanto A. R., Wagner J. G. “Pharmacokinetics of Highly Ionized Drugs III: Methylene Blue-Blood Levels in the Dog and Tissue Levels in the Rat Following Intravenous Administration,”. J. Pharm. Sci. 1972; 61: 1090–1094
- Priestly B. G., O'Reilly W. J. “Protein Binding and the Excretion of Some Azo Dyes in Rat Bile,”. J. Pharm. Pharmacol. 1966; 18: 41–45
- Axelson J. E., Gibaldi M. “Absorption and Excretion of Riboflavin in the Rat: An Unusual Example of Non-Linear Pharmacokinetics”. J. Pharm. Sci. 1972; 61: 404
- Mikkelson T. J., Chrai S. S., Robinson J. R. “Altered Bioavailability of Drugs in the Eye Due to Drug-Protein Interaction.,”. J. Pharm. Sci. 1973; 62: 1648–1653
- Bickel M. H., Steele J. W. “Binding of Basic and Acidic Drugs to Rat Tissue Subcellular Fractions,”. Chem.-Biol. Interact. 1974; 8: 151–162
- Bischoff K. B., Dedrick R. L., Zahahko D. S., Longstreth J. A. “Methotrexate Pharmacokinetics”. J. Pharm. Sci. 1971; 60: 1128
- Evans G. H., Wilkinson G. R., Shand D. G. “The Disposition of Propranolol IV, A Dominant Role for Tissue Uptake in the Dose-Dependent Extraction of Propranolol by the Perfused Rat Liver”. J. Pharmacol. Exp. Ther. 1973; 186: 447
- Glazko A. J., Chang T. “Diphenylhydantoin: Absorption, Distribution, and Excretion,”. Antiepileptic Drugs, D. M. Woodbury, J. K. Penry, R. P. Schmidt. Raven, New York 1972; 127–136
- Lightfoot R. W., Christian C. L. “Serum Protein Binding of Thyroxine and Diphenylhydantoin,”. J. Clin. Endocrinol. Metab. 1966; 26: 305–308
- Lund L., Berlin A., Lunde P. K. M. “Plasma Protein Binding of Diphenylhydantoin in Patients with Epilepsy. Agreement Between the Unbound Fraction in Plasma and the Concentration in the Cerebrospinal Fluid,”. Clin. Pharmacol. Ther. 1972; 13: 196–200
- Borondy P., Dill W. A., Change T., Buchanan R. A., Glazko A. J. “Effect of Protein Binding on the Distribution of 5,5-Diphenylhydantoin between Plasma and Red Cells,”. Ann. N. Y. Acad. Sci. 1973; 226: 82–87
- Eadie M. J., Tyrer J. H. “Plasma Levels of Anticonvulsants,”. Aust. N. Z. J. Med. 1973; 3: 290–303
- Viukari N. M. A., Tammisto P. “Diphenylhydantoin as an Anticonvulsant: Protein Binding and Fluctuation of the Serum and CSF Levels in 40 Mentally Subnormal Epileptics,”. J. Ment. Defic. Res. 1969; 13: 235–244
- Booker H. E., Darcey B. “Serum Concentrations of Free Diphenylhydantoin and Their Relationship to Clinical Intoxication,”. Epilepsia 1973; 14: 177–184
- Reidenberg M. M., Odar-Cederlof I., Cederlof C. v. Bahr, Borga O., Sjoqvist F. “Protein Binding of Diphenylhydantoin and Desmethylimipramine in Plasma from Patients with Poor Renal Function,”. N. Engl. J. Med. 1971; 285: 264–267
- Shoeman D. W., Azarnoff D. L. “The Alteration of Plasma Proteins in Uremia as Reflected in Their Ability to Bind Digitoxin and Diphenylhydantoin,”. Pharmacology 1972; 7: 169–177
- Reidenberg M. M., Affrime M. “Influence of Disease on Binding of Drugs to Plasma Proteins,”. Ann. N. Y. Acad. Sci. 1973; 226: 115–126
- Andreasen F. “Protein Binding of Drugs in Plasma from Patients with Acute Renal Failure,”. Acta Pharmacol. Toxicol. 1973; 32: 417–429
- Rane A., Lunde P. K. M., Jalling B., Yaffe S. J., Sjoqvist F. “Plasma Protein Binding of Diphenylhydantoin in Normal and Hyperbilirubinemic Infants,”. J. Pediatr. 1971; 78: 877–882
- Pruitt A. W., Dayton P. G. “A Comparison of the Binding of Drugs to Adult and Cord Plasma.,”. Eur. J. Clin. Pharmacol 1971; 4: 59–62
- Lunde P. K. M., Rene A., Yaffe S. J., Lund L., Sjoqvit F. “Plasma Protein Binding of Diphenylhydantoin in Man. Interaction with Other Drugs and the Effect of Temperature and Plasma Dilution,”. Clin. Pharmacol. Ther. 1970; 11: 846–855
- Letteri J. M., Mellk H., Louis S., Kutt H., Durante P., Glazko A. “Diphenylhydantoin Metabolism in Uremia,”. N. Engl. J. Med. 1971; 285: 648–652
- Boston Collaborative Drug Surveillance Program. “Diphenylhydantoin Side Effects and Serum Albumin Levels,”. Clin. Pharmacol. Ther. 1973; 14: 529–532
- Lund L., Lunde P. K., Rane A., Borga O., Sjoqvist F. “Plasma Protein Binding, Plasma Concentrations, and Effects of Diphenylhydantoin in Man,”. Ann. N. Y. Acad. Sci 1971; 179: 723–728
- Evans G. H., Nies A. S., Shand D. G. “The Disposition of Propranolol 111 Decreased Half-life and Volume of Distribution as a Result of Plasma Binding in Man, Monkey, Dog and Rat”. J. Pharmacol. Exp. Ther. 1973; 186: 114
- Evans G. H., Shand D. G. “Disposition of Propranolol VI, Independent Variation in Steady State Circulating Drug Concentration and Half-Life as a Result of Plasma Drug Binding in Man”. J. Pharmacol. Exp. Ther. 1973; 14: 494
- Sherwood L. M., Panis E. E. “Interaction of Adrenal and Gonadal Steroids with Proteins in Human Plasma,”. N. Engl. J. Med. 1969; 281: 658–665
- Peterson R. E., Wyngaarden J. B. “The Miscible Pool and Turnover Rate of Hydrocortisone in Man,”. J. Clin. Invest. 1956; 35: 552–561
- Peterson R. E., Wyngaarden J. B., Guerra S. L., Brodie B. B., Bunim J. J. “The Physiological Disposition and Metabolic Fate of Hydrocortisone in Man,”. J. Clin. Invest. 1955; 34: 1779–1794
- Burke C. W., Ronlet F. “Increased Exposure of Tissue to Cortisol in Late Pregnancy,”. Br. Med. J. 1970; 1: 657–659
- Araki Y., Yokota O., Kato T., Kasaaki K., Miyazaki T. “Dynamics of Synthetic Corticosteroids in Man,”. Steroid Dynamics, G. Pinus, T. Nakao, J. F. Tait. Academic, New York 1966; 463–480
- Wang D. Y., Bulbrook R. D. “The Binding of Steroids to Plasma Proteins in Normal Women and Women with Breast Cancer,”. Eur. J. Cancer 1969; 5: 247–253
- Lewis G. P., Burke C. W., Graves L., Jusko W. J. “Prednisone Side Effects and Serum Protein Levels,”. Lancet 1971; 2: 778–781
- Tait J. F., Burstein S. “In vivo Studies of Steroid Dynamics in Man,”. Hormones (New York) 1964; 5: 441–557
- Yates F. E., Brennan R. D., Urquhart J. “Adrenal Glucocorticoid Control System,”. Fed. Proc. 1969; 28: 71–83
- Paterson J. Y. F. “The Rate Constants for the Interaction of Cortisol and Trans-cortin and the Rate of Dissociation of Transcortin-Bound Cortisol in the Liver,”. J. Endocrinol. 1973; 56: 551–570
- Levy G., Yacobi A. “Effect of Plasma Protein Binding on Elimination of Warfarin,”. J. Pharm. Sci. 1974; 63: 805–806
- Levy G. “Relationship between Plasma Protein Binding, Distribution, and Anticoagulant Action of Dicumarol,”. Ann. N. Y. Acad. Sci. 1973; 226: 195–199
- Jähnchen E., Levy G. “Relationship between Distribution, Elimination, and Anticoagulant Action of Dicumarol,”. J. Pharmacol. Exp. Ther. 1974; 188: 293–299
- Lewis R. J., Spivak M., Spaet T. H. “Warfarin Resistance,”. Am. J. Med. 1967; 42: 620–624
- Woselait W. D., Garten S. “Computation of Unbound Anticoagulant Values in Plasma.,”. Res. Commun. Chem. Pathol. Pharmacol. 1972; 3: 285–291
- Levy G., Nagashima R. “Comparative Pharmacokinetics of Coumarin Anticoagulants VI: Effect of Plasma Protein Binding on the Distribution and Elimination of Bishydroxycoumarin by Rats,”. J. Pharm. Sci. 1969; 58: 1001–1004
- Nagashima R., Levy G., Sarcione E. J. “Comparative Pharmacokinetics of Coumarin Anticoagulants III. Factors Affecting the Distribution and Elimination of Bishydroxycoumarin in Isolated Perfusion Studies”. J. Pharm. Sci. 1968; 57: 1881
- Seydel J. K. “The Relationship of Pharmacokinetic Properties of Some Sulfonamides to Certain Physicochemical Parameters”. Hoc. 6th Int. Congr. Chemother. 1970; 881
- Wiseman E. H., Nelson E. “Correlation of in vivo Metabolism Rate and Physical Properties of Sulfonamides”. J. Pharm. Sci. 1964; 53: 992
- Jusko W. J., Dittert L. W. “Integral Coefficients of Multi-Compartmental Pharmacokinetic Models,”. Chemotherapy 1972; 17: 109–120
- Colaizzi J. L., Klink P. R. “pH-Partition Behavior of Tetracycline,”. J. Pharm, Sci. 1969; 58: 1184–1189
- Wittenau S. M. v., Yeary R. “The Excretion and Distribution in Body Fluids of Tetracycline after I. V. Administration to Dog,”. J. Pharmacol. Exp. Ther. 1963; 140: 258–266
- Kunin C. W. “Comparative Serum Binding, Distribution, and Excretion of Tetracycline and a New Analogue, Methacycline,”. Proc. SOC. Exp. Bid. Med. 1962; 110: 311–315
- Rosenblatt J. E., Barrett J. E., Brodie J. L., Kirby W. M. M. “Comparison of in vitro Activity and Clinical Pharmacology of Doxycycline with Other Tetracyclines,”. Antimicrob. Agents Chemother. 1966; 6: 134–141
- Kunin C. W., Dornbash A. C., Finland M. “Distribution and Excretion of 4 Tetracycline Analogues in Normal Young Men,”. J. Gin. Invest. 1959; 38: 1950–1963
- Steigbigel N. H., Reed C. W., Finland M. “Absorption and Excretion of 5 Tetracycline Analogues in Normal Young Men”. Am. J. Med. Sci. 1968; 255: 296
- Ritschel W. A. “Biological Half-Lives and Their Clinical Applications,”. Perspectives in Clinical Pharmacy, D. E. Francke, H. A. K. Whitney. Drug Intelligence Publications, Hamilton, Illinois 1972, Chap. 16
- Griffith R. S., Black H. R. “Comparison of the Blood Levels Obtained After Single and Multiple Doses of Erythromycin Estolate and Erythromycin Sterate”. Am. J. Med Sci. 1964; 247: 69
- Wiegand R. G., Chun A. H. C. “Serum Protein Binding of Erythromycin and Erythromycin-2-Propionate Ester”. J. Pharm. Sci. 1972; 61: 425
- Runkel R., Forchielli E., Sevelius H., Chaplin M., Segre E. “Non-Linear Plasma Levels Response to High Doses of Naproxen”. Clin. Pharmacol. Ther. 1974; 15: 261
- Glassman A., Hurwie M. J., Perel J. M. “Plasma Binding of Imipramine and Clinical Outcome”. Am. J. Psychiatry 1973; 130: 1367
- The Boston Collaborative Drug Surveillance Program. “Diphenylhydantoin Side Effects and Serum Albumin Levels”. Clin. Pharmacol. Ther. 1973; 14: 529
- Stovner J., Theodorsen L., Bjelke E. “Sensitivity to Tubocurarine and Alcuronium with Special Reference to Plasma Protein Patterns,”. Br. J. Anaesth. 1971; 43: 385–391
- Stont R. J. “Some Clinical Evidence for a Quantitative Relationship between Dose of Relaxant and Plasma Protein”. West Indian Med. J. 1963; 12: 256
- Edwards R., Ellis F. R. “Clinical Significance of Thiopentone Binding to Haemoglobin and Plasma Proteins,”. Br. J. Anaesth. 1973; 45: 891–893
- Grausz H., Schmid R. “Reciprocal Relation between Plasma Albumin Level and Hepatic Sulfobromophthalin Removal,”. N. Engl. J. Med. 1971; 284: 1403–1406
- Mendenhall C. L., Leevy C. M. “False-Negative Bromsulfalein Test”. N. Engl. J. Med. 1961; 264: 431
- Kawasaki H., Oma H., Sakaguchi S., Tominaga K., Hirayama C. “Abnormal Binding of Indocyanine Green with Serum Proteins in a Patient with Delayed ICG Clearance”. Clin. Chem. Acta 1973; 47: 3943
- Payne R. B., Little A. J., Williams R. B., Milner J. R. “Interpretation of Serum CA++ in Patients with Abnormal Serum Proteins”. Br. Med. J. 1973; 4: 643–646
- Berry E. M., Gupta M. M., Burns R. R. “Variation in Plasma Calcium with Induced Changes in Plasma Specific Gravity, Total Protein and Albumin,”. Br. Med. J. 1973; 4: 640–643
- Pedersen K. O. “On the Cause and Degree of Intraindividual Serum CA++ Variability,”. Scand. J. Clin. Lab. Invest. 1972; 30: 191–199
- Crawford J. S. “Drug Binding by Serum Albumin: Implication of Some Recent Observations”. Br. J. Anaesth. 1969; 41: 543
- Crawford J. S., Hooi H. W. Y. “Binding of Bromosulphthalein by Serum Albumin from Pregnant Women, Neonates, and Subjects on Oral Contraceptives”. Br. J. Anaesth. 1968; 40: 723
- Crawford J. S., Hooi H. W. Y. “Binding of Salicylic Acid and Sulphanilamide in Serum from Pregnant Patients, Cord Blood, and Subjects Taking Oral Contraceptives”. Br. J. Anaesth. 1968; 40: 825
- Gretch M., Jusko W. J. “Interpretation of Drug Binding Changes in Relation to Protein Concentration”. Br. J. Anaesth. 1974; 46: 545
- Reidenberg M. M., Affrime M. “Influence of Disease on Binding of Drugs to Plasma Proteins,”. Ann. N. Y. Acad. Sci. 1973; 226: 115–126
- Andreasen F. “Protein Binding of Drugs in Plasma from Patients with Acute Rend Failure,”. Acta Pharmacol. Toxicol. 1973; 32: 417–429
- Campion D. S. “Decreased Drug Binding by Serum Albumin During Renal Failure,”. Toxicol. Appl. Pharmacol. 1973; 25: 391–397
- Odarderlöf I.-C., Ĺunde P., Sjogvist F. “Abnormal Pharmacokinetics of Phenytion in a Patient with Uremia”. Lancet 1970; 1: 831
- Reidenberg M. M. “Protein Binding of Diphenylhydantoin and Dismethyl-imipramine in Plasma from Patients with Poor Renal Function,”. N. Engl. J. Med. 1971; 285: 264–267
- Shoeman D. W., Azarnoff D. L. “The Alteration of Plasma Proteins in Uremia as Reflected in Their Ability to Bind Digitoxin and DPH,”. Pharmacology 1972; 7: 169–177
- Letteri J. M., Mellk H., Louis S., Kutt H., Durante P., Glazko A. “Diphenylhydantoin Metabolism in Uremia”. N. Engl. J. Med. 1971; 285: 648
- Bridgeman J. F., Rosen S. M., Thorp J. M. “Complication During Clofibrate Treatment of Nephrotic-Syndrome Hyperlipoproteinemia,”. Lancet 1972; 506
- Losowsky M. S., Kenward D. H. “Lipid Metabolism in Acute and Chronic Renal Failure”. J. Lab. Cain. Med. 1968; 71: 736
- Rudman D., Bixler T. J., Del Rio A. E. “Effects of FFA on Binding of Drugs by Bovine Serum Albumin, by Human Serum Albumin, and by Rabbit Serum”. J. Pharmacol. Exp. Ther. 1971; 176: 261
- Dromgoole S. H. “The Effects of Hemodialysis on the Binding Capacity of Albumin,”. Clin. Chim. Acta 1973; 46: 469–472
- Ehrnebo M., Agurell S., Jailing B., Boreus L. O. “Age Differences in Drug Binding by Plasma Proteins: Studies on Human Foetuses, Neonates, and Adults,”. Eur. J. Clin. Pharmacol. 1971; 3: 189–193
- Pruitt A. W., Dayton P. G. “A Comparison of the Binding of Drugs to Adult and Cord Plasma,”. Eur. J. Clin. Pharmacol. 1971; 4: 59–62
- Mather L. E., Long G. J., Thomas J. “The Binding of Bupivacaine to Material and Foetal Plasma Proteins,”. J. Pharm. Pharmacol. 1971; 23: 359–365
- Tucker G. T., Boyes R. W., Bridenbaugh P. O., Moore D. C. “Binding of Anilide-Type Local Anesthetics in Human Plasma,”. Anesthesiology 1970; 33: 304–314
- Chignell C. F., Vesell E. S., Starkweather D. K., Berlin C. M. “The Binding of Sulfaphenazole to Fetal, Neonatal, and Adult Human Plasma Albumin,”. Clin. Pharm. Ther. 1971; 12: 897–901
- Kucera J. L., Bullock F. J. “The Binding of Salicylate to Plasma Protein from Several Animal Species,”. J. Pharm. Pharmacol. 1969; 21: 293–296
- Sturman J. A., Smith M. J. H. “The Binding of Salicylate to Plasma Proteins in Different Species”. Bid. 1967; 19: 621
- Keen P. M. “The Binding of 3 Penicillins in the Plasma of Several Mammalian Species as Studied by Ultrafiltration at Body Temperature,”. Br. J. Pharmacol. 1965; 25: 507–514
- Anton A. H. “The Relation between the Binding of Sulfonamides to Albumin and Their Antibacterial Efficacy,”. J. Pharmacol. Exp. Ther. 1960; 129: 282–290
- Genazzani E., Pagnini G. “Binding Capability of Various Sulfonamides to Serum of Different Animal Species,”. Am. J. Vet. Res. 1963; 24: 1212–1216
- Chignell C. F., Starkweather D. K. “Species Differences in the Binding of Phenylbutazone to Plasma Albumin,”. Pharmacology 1971; 5: 235–244
- Conard G. J., Haavik C. O., Finger K. F. “Binding of 5, 5-Diphenylhydantoin and Its Major Metabolites to Human and Rat Plasma Protein,”. J. Pharm. Sci. 1971; 60: 1642–1646
- Boggot J. D., Davis L. E., Neff C. A. “Extent of Plasma Protein Binding of Amphetamine in Different Species”. Biochem. Pharmacol. 1972; 21: 1813
- Borga O., Azarnoff D. L., Sjoqvist F. “Species Differences in the Plasma Protein Binding of Desipramine”. J. Pharrn. Pharmacol. 1968; 20: 571
- Curry S. H. “Relation between Binding of Plasma Proteins, Apparent Volume of Distribution and Rate Constant of Disposition and Elimination for Chlorpromazine in 3 Species”. J. Pharrn. Pharmacol. 1972; 24: 819
- Evaluation of Drug Interactions. American Pharmaceutical Association, Washington, DC 1973
- Aggeler P. M., Reillybong R. A. O'L., Kowitz P. E. “Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone,”. N. Engl. J. Med. 1967; 276: 496–501
- Sellers E. M., Koch-Weser J. “Potentiation of Warfarin Induced Hypothrombonemia by Chloral Hydrate”. N. Engl. J. Med. 1970; 283: 827
- Boston Collaborative Drug Surveillance Rogram. “Interaction between Chloral Hydrate and Warfarin,”. Bid. 1972; 286: 53–55
- Anton A. H. “A Drug Induced Change in the Distribution and Renal Excretion of Sulfonamides,”. J. Pharmacol. Exp. Ther. 1961; 134: 291–303
- Odell G. B. “Influence of Binding on the Toxicity of Bilirubin,”. Ann. N. Y. Acad. Sci. 1973; 226: 225–237
- Christensen L. K. “Sulphaphenazole Induced Hypoglycemic Attacks in Tolbutamide Treated Diabetics,”. Lancet 1963; 2: 1298–1301
- Dixon R. L., Henderson E. S., Rall D. P. “Plasma Protein Binding of Methotrexate and Its Displacement by Various Drugs”. Fed. Proc. 1965; 24: 454
- Borga O., Azarnoff D. L., Forshell G. P., Sjoqvist F. “Plasma Protein Binding of Tricyclic Antidepressants in Man,”. Biochem. Pharmacol. 1969; 18: 2135–2143
- Laser E. C., Martel G. E., Granke R. C. “The Roentgen Contrast Media Potentiation of Nembutal Anesthesic in Rats,”. Am. J. Roentgenol., Radium Ther. Nucl. Med. 1964; 91: 453–460
- Hussar D. A. Drug Interactions. Lea and Febiger, Philadelphia 1973
- McArthur J. N., Dawkens P. D., Smith M. J. H. “The Displacement of L-Tryptophan and Dipeptides from Bovine Albumin in vitro and from Human Plasma in vivo by Antirheumatic Drugs,”. J. Pharm. Pharmacol. 1971; 23: 393–398
- Aylard M., Maddock J. “Total and Free Plasma Tryptophan Concentration in Rheumatoid Disease”. J. Pharm. Pharmacol. 1973; 25: 570
- Dollery C. T., Smith D. E., Muggleton D. F. “Action of Chlorthiazide on the Distribution, Excretion, and Hypotensive Effect of Pempidine in Man,”. J. Pharmacol. 1961; 17: 488–501
- Bluestone R. I., Kippen I., Klinenberg J. R. “Effect of Drugs on Urate Binding to Plasma Proteins”. Br. Med. d. 1969; 4: 590
- Whitehouse M. W., Kippen I., Klineberg J. R., Schlosstein L., Campion D. S., Bluestone R. “Increasing Excretion of Urate with Displacing Agents in Man”. Ann. N. Y. Acad. Sci. 1973; 226: 309
- Whitehouse M. W., Kippen I., Klineberg J. R. “Biochemical Properties of Anti-Inflammatory Drugs, XI, Inhibition of Urate Binding to Human Albumin by Salicylate and Phenylbutazone Andggs and Some Novel Anti-Inflammatory Drugs,”. Biochern. Pharmocol. 1971; 20: 3309–3320
- Dunn W. J. “Specificity of Binding to Human Serum Albumin,”. J. Pharm. Sci. 1973; 62: 1575–1577
- Dunn W. J. “Binding of Certain Non-Steroidal Anti-Inflammatory Agents and Uricosuric Agents to Human Serum Albumin”. J. Med. Chem. 1973; 16: 484
- Benowitz N., Forsyth R. P., Melmon K. L., Rowland M. “Lidocaine Disposition Kinetics in Monkey and Man. I. Prediction by a Perfusion Model,”. Clin. Pharmacol. Ther. 1974; 16: 87–98
- Gabay S., Huang P. C. “The Binding Behavior of Phenothiazine and Structurally Related Compounds to Albumin from Several Species. The Phenothiazines and Structurally Related Drugs, I. S. Forrest, C. J. Carr, E. Usdin. Raven, New York 1974
- Scholtan V. W., Schobmann K., Rosenkranz H. “Die Bindung von Steroid Hormonen und von Steroid Quanyl-Hydrazonen an Serum-Albumin,”. Arzneim.- Forsch. 1968; 18: 1
- Biggs J. T., Levy L., Gordon G. R., Peters J. H. “Binding of Dapsone (DDS) and Monacetyldapsone (MADDS) by Plasma of Animals and Man”. Int. J. Leprosy 1972; 39: 99
- Borga O., Azarnoff D., Forshell G. P., Sjogvest F. “Plasma Protein Binding of Tricyclic Antidepressants in Man”. Biochem. Pharmacol. 1969; 18: 2135
- Bird A. E., Marshall A. C. “Correlation of Serum Binding of Penicillin with Partition Coefficient,”. Biochem. Pharmacol. 1967; 16: 2275–2290
- Hansch C., Kiehs K., Lawrence G. L. “The Role of Substituents in the Hydrophobic Binding of Phenols by Serum and Mitochondrial Proteins”. J. Am. Chem. Soc. 1965; 87: 5770
- Fujita T., Hansch C. “Analysis of the Structure Activity Relationship of the Sulfonamide Drugs Using Substituent Constant”. J. Med. Chem. 1967; 10: 993
- Fujita T. “Hydrophobic Binding of Sulfonamide Drugs with Serum Albumin”. J. Med. Chem. 1972; 15: 1049
- Pelkonen O., Karki N. T. “Effect of Physicochemical and Pharmacokinetic Properties of Barbiturates on the Induction of Drug Metabolism,”. Chem.-Biol. Interac. 1973; 7: 93–99
- Hansch C. “Intermolecular Reactions Between Proteins and Organic Compounds,”. Proc. Int. Congr. Chemother. 1970; 4: 113–118
- Penniston J. T., Beckett L., Bentley D. L., Hansch C. “Passive Permeation of Organic Compounds Through Biological Tissue: A Non-Steady State Theory,”. Mol. Pharmacol. 1969; 5: 333–341
- Douglas J. F., Bradshaw W. H., Ludwig B. J., Powers D. “Interaction of Plasma Proteins with Related 1,3-Propanediol Dicarbomates”. Biochem. Pharmacol. 1964; 13: 537
- Teresi J. D., Luck J. M. “The Combination of Organic Anions with Serum Albumin VIII Fatty Acid Salts”. J. Biol. Chem. 1952; 194: 823
- Helmer F., Kiehs K., Hansch C. “The Linear Free-Energy Relationship between Partition Coefficient and the Binding and Conformational Perturbation of Macromolecules by Small Organic Compounds”. Biochemistry 1968; 7: 2858
- Vandenbelt J. M., Hansch C., Church C. “Binding of Apolar Molecules by Serum Albumin”. J. Med. Chem. 1972; 15: 787
- Kiehs K., Hansch C., Moore L. “The Role of Hydrophobic Bonding in the Binding of Organic Compounds by Bovine Hemoglobin”. Biochemistry 1966; 5: 2602
- Dearden J. C., Tomlinson E. “Physicochemical Studies of Analgesics: The Protein Binding of Some p-Substituted Acetanilides,”. J. Pharm. Pharmacol. 1970; 22: 535–595
- Dearden J. C., Tomlinson E. “A New Buccal Absorption Model,”. J. Pharm. Pharmacol. 1971; 23: 685–725
- Hansch C., Fujita T. “A Method for the Correlation of Biological Activity and Chemical Structure”. J. Am. Chem. Soc. 1964; 86: 1616
- Joos R. W., Hall W. H. “Determination of Binding Constants of Serum Albumin for Penicillin”. J. Pharmacol. Exp. Ther. 1969; 166: 113
- Mais R. F., Keresztesgy S.-N., Zaroslinski J. F., Oester Y. T. “Interpretation of Protein-Drug Interaction through Fraction Bound and Relative Contribution of Secondary Sites,”. J. Pharm. Ski. 1974; 63: 1423–1427
- Shah V. P., Wallace S. M., Riegelman S. “Microultrafitration Technique for Drug-Protein Binding Determination in Plasma,”. J. Pharm. Ski. 1974; 63: 1364–1367
- Biggs J. T., Levy L. “Binding of Dapsone and Monoacetyl Dapsone by Human Plasma Protein”. Proc. Soc. Exp. Biol. Med. 1971; 137: 692
- Peets E. A., Slaub M., Symchowicz S. “Plasma Binding of Betamethasone- 3H, Dexamethasone-3H, and Cortisol-14C: A Comparative Study,”. Biochem. Pharmacol. 1969; 18: 1655–1663
- Elion G. B., Kovensky A., Hitchings G. H., Metz E., Rundles W. “Metabolic Studies of Allopurinol an Inhibitor of Xanthine Oxidase”. Biochem. Pharmacol. 1966; 15: 863
- Ghoneim M. M., Sister Kramer E., Bannow R., Pandya H., Routh J. I. “Binding of d-Tubocurarine to Plasma Proteins in Normal Man and in Patients with Hepatic or Renal Disease”. Anesthesiology 1973; 39: 410
- Curry S. H., Riddal D., Gordon J. S., Simpson P., Binns T. B. “Disposition of Glutethimide in Man,”. Clin. Pharmacol. Ther. 1971; 12: 849–857
- Curry S. H. “Plasme Protein Binding of Chlorpromazine,”. J. Pharm. Pharmacol. 1970; 22: 193–197
- Wohlqvist M., Nelson I. M., Sandberg F., Agurell A., Granstrand B. “Binding of dl-Tetrahydrocannabinol to Human Plasma Proteins,”. Biochem. Pharmacol. 1970; 19: 2579–2584
- Sellers E. M., Koch-Weser J. “Binding of Diazoxide and Other Benzothiadimines to Human Albumin,”. Biochem. Pharmacol. 1974; 23: 553–566
- Franksson G., Anggard E. “Plasma Protein Binding of Amphetamine, Catecholamines and Related Compounds,”. Acta Pharmacol. Toxicol. 1970; 28: 209–214
- Olsen G. D. “Methadone Binding to Human Plasma Albumin,”. Science 1972; 176: 525–526
- Unger W. G. “Binding of Prostaglandins to Human Serum Albumin”. J. Pharm. Pharmacol. 1972; 24: 470
- Wang D. Y., Bulbrook R. D. “The Binding of Steroids to Plasma Proteins in Normal Women and Women with Breast Cancer,”. Eur. J. Cancer 1969; 5: 247–253
- Gordon R. C., Regamey C., Kirby W. M. M. “Serum Protein Binding of the Aminoglycoside Antibiotics.,”. Antimicrob. Agents Chemother. 1972; 2: 214–216
- Nambu N., Nagai T. “Binding of Phenothiazines to Bovine Serum Albumin and Related Phenomena,”. Chem. Pharm. Bull. 1970; 20: 2463–2470
- Craig W. A., Kunin C. W. “Trimethaprin-Sulfamethoxazole: Pharmacodynamic Effects of Urinary pH and Impaired Renal Function-Studies in Humans,”. Ann. Intern. Med. 1973; 78: 491–497
- Branstad J. O., Meresaai V., Agren A. “Complex Formation between Macromolecules and Drugs, Part VII, The Binding of Some Barbiturates to Human Serum Albumin at Varying pH,”. Acta Pharm. Suec. 1972; 9: 129–134
- Wada S., Tomioka S., Moriguchi I. “Protein Binding, VI, Binding of Phenols to Bovine Serum Albumin,”. Chem. Pharm. Bull. 1969; 17: 320–323
- Loo T. L., Phil D., Luce J. K., Sullivan M. P., Frei E. “Clinical Pharmacologic Observations on 6-Mercaptopurine and 6-Methylthiopurine Ribonucleoside,”. Clin. Pharmacol. Ther. 1968; 9: 180–194
- Bodey G. P., Vallejos C., Stewart D. “Flucloxacillin: New Semi-synthetic Isoxazolyl Penicillin,”. Clin. Pharmacol. Ther. 1972; 13: 512–515
- Moriguchi I. “Protein Binding, II, Binding of Aromatic Carboxcyclic Acids to BSA”. Chem. Pharm. Bull. 1968; 16: 597
- Moriguchi I., Wada S., Nishizawa T. “Protein Binding, III, Binding of Sulfonamides to Bovine Serum Albumin”. Chem. Pharm. Bull. 1968; 16: 601
- Green H. O., Moritz J., Lack L. “Binding of Sodium Taurocholate by Bovine Serum Albumin”. Biochem. Biophys. Acta 1971; 231: 550
- Conard G. J., Haavik C. O., Finger K. F. “Binding of 5, 5-Diphenylhydantoin and Its Major Metabolites to Human and Rat Plasma Protein”. J. Pharm. Sci. 1971; 60: 1642
- Danon A., Sapira J. D. “Binding of Catecholamines to Human Serum Albumin”. J. Pharmacol. Exp. Ther. 1972; 182: 295
- Attallah A. A., Schussler G. C. “Prostaglandin Binding in Human Serum Following the Polarity Rule”. Prostaglandins 1973; 4: 479
- Raz A. “Interaction of Prostaglandins with Blood Plasma Protein”. Biochem. J. 1972; 130: 631
- O'Reilly R. A. “Interaction of the Anticoagulant Drug Warfarin and Its Metabolites with Human Plasma Albumin,”. J. Clin. Invest. 1969; 48: 193
- Rubin A., Warrick P., Wolen R. L., Chernish S. M., Ridolfo A. S., Gruber J. R. “Physiological Disposition of Fenoprofen in Man, 3, Metabolism and Protein Binding of Fenoprofen,”. J. Pharmacol. Exp. Ther. 1972; 183: 449–457
- Howell A., Sutherland R., Robinson G. N. “Effect of Protein Binding on Levels of Ampicillin and Cloxacillin in Synovial Fluid”. Clin. Pharmacol. Ther. 1972; 13: 724
- Tucker G. T., Boyer R. N., Bridenbaugh P. O., Moore D. C. “Binding of Anilide-Type Local Anesthetics in Human Plasma”. Anesthesiology 1970; 33: 287
- Campbell I. C., Todrich A. “Plasma Protein Binding of Tricyclic Antidepressant Drugs”. J. Pharm. Pharmacol. 1970; 22: 227
- Walker S. R. “Influence of Protein Binding on the Excretion of Some Sulfanilamidopyrimidines in Man,”. J. Pharm. Pharmacol. 1970; 22: 574–577
- Sharples D. “The Binding of Chlorpromazine to Human Serum Albumin”. J. Pharm. Pharmacol. 1974; 26: 640
- Elofsson R., Nilsson S. O., Kluczykowska B. “Complex Formation between Macromolecules and Drugs, V, A Study of Human Serum Albumin (HSA) Binding of Some 4-Sulfanilamidopyrimidines and 2Sulfanilamidopyrimidines”. Acta Pharm. Suec. 1971; 8: 465
- Elofsson R., Nilsson S. O., Argen A. “Complex Formation between Macro-molecules and Drugs, IV, Binding of Sulfa Drugs to Human Serum Albumin at Varying pH Values,”. Hid. 1970; 7: 473–482
- Baggot J. P., Davis L. E., Neff C. A. “Extent of Plasma Binding of Amphetamines in Different Species”. Biochem. Pharmacol. 1972; 21: 1813
- Rosenthal H. E., Pietrzak E., Siaunwhite W. R., Sandberg A. A. “Binding of Estrone Sulfate in Human Plasma,”. J. Clin. Endocrinol. Metab. 1972; 34: 805–813
- Powis G. “A Study of the Interaction of Tetracycline with Human Serum Lipo-protein and Albumin,”. J. Pharm. Pharmacol. 1974; 26: 113–118
- Wosilait W. D., Garten S. “A Theoretical Study of Multiple Drug-Protein Binding Data Exemplified by the Dicumarol Serum Albumin Interaction”. Res. Commun. Chem. Pathol. Pharmacol. 1972; 3: 535
- Guttler F., Tybreng L., Engberg-Pedersen H. “Interaction of Albumin and Fusidic Acid,”. Br. J. Pharmacol 1971; 43: 151–160
- Kraghnsen V.-H., Moller J. V. “Protein Binding of Small Molecules I, Effect of pH and Inorganic Salts on the Combination of Phenol Red with Protein”. Biochem. Biophys. Acta 1973; 298: 438
- Foney A. W., Krinpel B., Blair A. D., Culter R. E. “Furosemide Concentration in Serum and Urine and Its Binding by Serum Protein as Measured Fluoro-metrically”. Clin. Chem. 1974; 20: 152
- van der Kleijn E. “Protein Binding and Lipophilic Nature of Ataractics of the Meprobamate and Diazepine Group.”. Arch. Int. Pharmacodyn. 1969; 179: 225
- Solomon H. M., Schrogie J. J., Williams D. “The Displacement of Phenylbutazone 14C and Warfarin 14C from Human Albumin by Various Drugs and Fatty Acids,”. Biochem. Pharmacol. 1968; 17: 143–151
- Saslaw S. “Studies on Therapy of Staphylococcal Infection in Monkeys, V, Comparison of Cephalexin, Oxacillin, Cloxacillin, Decloxacillin, and Nafcillin,”. Am. J. Med. Sci. 1970; 259: 143–152
- Sellers E. M., Koch-Weser J. “Displacement of Warfarin from Human Albumin by Diazoxide and Ethacrynic, Mefenamic, and Nalidixic Acids”. Clin. Pharmacol. Ther. 1970; 11: 524529
- Ronwin E., Zacchei A. G. “Binding of Ethacrynic Acid to Bovine Serum Albumin,”. Can. J. Biochem. 1967; 45: 1433–1443
- Hays M., Green F. “In vitro Studies of TC-99-M-Pertechnetate Binding by Human Serum and Tissue,”. J. Nucl. Med. 1973; 14: 149–158
- Kuntzman R., Tsai I., Burns J. J. “Importance of Tissue and Plasma Binding in Determining the Retention of Norchlorcyclizine and Norcyclizine in Man, Dog, Rat,”. J. Pharm. Exp. Ther. 1967; 158: 332
- Witiak D. T., Whitehouse M. W. “Species Differences in the Albumin Binding of 2,4,6-Trinitrobenzaldehyde, Chlorophenoxyacitate Acids, 2-(4′-Hydroxybenzeneazo) Benzoic Acid and Some Other Acidic Drugs–The Unique Behavior of Rat Plasma Albumin,”. Biochem. Pharmacol. 1969; 18: 971–976
- Dayton P. G., Perel J. M., Landrau M. A., Brand L., Mark E. C. “The Relationship between the Binding of Thiophental to Plasma and Its Distribution into Adipose Tissue in Man”. Biochem. Pharmacol. 1967; 16: 2321
- DiSalle E., Pacifici G. M., Morselli P. L. “Studies on Plasma Protein Binding of Carbamazepine,”. Pharmacol. Res. Commun. 1974; 6: 193–202
- Schlosstein L. H., Kippen I., Whitehouse M. W., Bluestone R., Klinenberg J. R. “Studies with Some Novel Uricosuric Agents and Their Metabolites,”. J. Lab. Clin. Med. 1973; 82: 412–418
- Alexanderson B., Borga O. “Interindividual Differences in Plasma Protein Binding of Nortriptyline in Man–A Twin Study”. Eur. J. Clin. Pharmacol 1972; 4: 196
- Lund L., Berlin A., Lunde P. K. M. “Plasma Protein Binding of Diphenylhydantoin in Patients with Epilepsy”. Clin. Pharmacol. Ther. 1971; 13
- Booker H. E., Darcey B. “Serum Concentrations of Free Diphenylhydantoin and Their Relationship to Clinical Intoxication”. Epilepsia 1973; 14: 177
- Donigian D. W., Owellen R. J. “Interaction of Vinblastine, Vincristine, and Colchicine with Serum Proteins,”. Biochem. Pharmacol. 1973; 22: 2113–2119
- Judis J. “Binding of Sulfonylureas to Serum Proteins,”. J. Pharm. Sci. 1972; 61: 89–93
- Jusko W. J., Levy G. “Plasma Protein Binding of Riboflavin and Riboflavin 5′-Phosphate in Man”. J. Pharm. Sci. 1969; 58: 58
- Ma J. K. H., Jun H. W., Luzzi A. “Tetracycline Binding to Bovine Serum Albumin Studied by Fluorescent Technique”. J. Pharm. Sci. 1973; 8: 126
- Esposito M., Rosso R., Santi L. “Plasma Protein Binding of Antineoplastic Drugs in Rats and Humans”. IRCS 1974; 2: 1180
- Cho M. J., Mitchell A. G., Pernarowski M. “Interaction of Bishydroxycoumarin with Human Serum Albumin,”. J. Pharm. Sci. 1971; 60: 196–200
- Patel N. K., Sheen P. C., Taylor K. E. “Studies on Protein Binding, I, Interaction of pHydroxybenzoic Acid Esters with Bovine Serum Albumin,”. Pharm. Sci. 1968; 57: 1370–1374
- Kripalani K. J., Sorby D. L. “Binding of Cortisol and Its Degradation Products by Human Serum Albumin”. Pharm. Sci. 1967; 56: 687
- Gordon R. C., Ragamey C., Kirby W. M. M. “Serum Protein Binding of Erythromycin, Lincomycin, and Clindamycin”. Pharm. Sci. 1973; 62: 1074
- Crook M. J., Brown K. F. “Binding of Sulfonylureas to Serum Albumin”. Pharm. Sci. 1973; 62: 1904
- Steward J. T., Story J. L. “In vitro Binding of Pentylenetetrazol to Plasma Protein”. Pharm. Sci. 1972; 61: 652
- Kruglstein J., Meiler W., Staab J. “Hydrophobic and Ionic Interaction of Phenothiazine Derivatives with Bovine Serum Albumin”. Biochem. Pharmacol. 1972; 21: 985
- Chignell C. F. “Optical Studies of Drug Protein Complexes, II, Interaction of Phenylbutazone and Its Analogues to Human Serum Albumin”. Mol. Pharmacol. 1969; 5: 244
- Israili Z. H., Perel J. M., Cunninghan R. F., Dayton P. G., Yu T. F., Gutman A. B., Long K. R., Long R. C. “Metabolite of Probenecid: Chemical, Physical, and Pharmacological Studies”. J. Med. Chem. 1972; 15: 709
- Mark L. C., Perel J. M., Brand L., Dayton P. G. “Studies with Thiohexital an Anesthetic Barbiturate Metabolized with Unusual Rapidity in Man”. Anesthesiology 1968; 29: 1159
- Lukas D. S., DeMartino A. “Binding of Digitoxin and Some Related Cardenolides to Human Plasma Protein,”. J. Clin. Invest. 1969; 48: 1041
- Noval J. J., Champion V. “Equilibrium Dialysis Study of the Binding of Chlorpromazine to Serum Proteins,”. Res. Commun. Chem. Pathol. Pharmacol. 1973; 6: 123–135
- Agren A., Elofsson R., Nilsson S. O. “Some Physicochemical Factors Influencing the Binding of Sulfonamides to Human Albumin in vitro”. Acta Pharmacol. Toxicol, Suppl. 1970; 29(3): 49
- Hsu Par-Lin, Ma J. K. H., Luzzi L. A. “Interaction of Sulfonylureas with Plasma Proteins”. J. Pharm. Sci. 1974; 63: 571
- Nazareth R. I., Sokoloski T. D., Witiak D. T., Hopper A. T. “Biological Significance of Serum Albumin Binding Parameters Determined in vitro from Clofibrate Related Hypolipemic Drugs: Use of 2-(4′-Hydroxybenzenao) Benzoic Acid to Mirror L-Tyrosine Binding to and Displacement from Serum Albumin”. J. Pharm. Sci. 1974; 63: 203
- Campion D. S., Olsen R. “Measurement of Drug Displacement by Continuous Ultrafiltration”. J. Pharm. Sci. 1974; 63: 249
- Hsu Par-Lin, Ma J. K. H., Jun H. W., Luzzi L. A. “Structure Relationship for Binding of Sulfonamides and Penicillins to Bovine Serum Albumin by Fluorescence Probe Technique”. J. Pharm. Sci. 1974; 63: 27
- Weder H. J., Bickel M. H. “Interaction of Drugs with Proteins, I, Binding of Tricyclic Thymoleptics to Human and Bovine Plasma Protein”. J. Pharm. Sci. 1970; 59: 1505
- Weder H. J., Bickel M. H. “Interaction of Drugs with Proteins, II, Experimental Methods, Treatment of Experimental Data, and Thermodynamics of Binding Reactions of the Thymoleptic Drugs and Model Dyes”. J. Pharm. Sci. 1970; 59: 1563–1569
- Kostenbauder H. B., Bakal S. M., Jawad M. J. “Binding of Salicylate to Crystalline Bovine Serum Albumin and to Fraction V Bovine Serum Albumin”. J. Pharm. Sci. 1970; 59: 1047
- Meyer M. C., Guttman D. E. “Dynamic Dialysis as a Method for Studying Protein Binding, II, Evaluation of the Method with a Number of Binding Systems.”. J. Pharm. Sci. 1970; 59: 39
- Crawford J. S., Hooi H. W. Y. “Binding of BSP by Serum Albumin from Pregnant Women, Neonates, and Subjects on Oral Contraceptives”. Br. J. Anaesth. 1968; 40: 723
- Crawford J. S., Hooi H. W. Y. “Binding of Salicylic Acid and Sulphanilamide in Serum from Pregnant Patients, Cord Blood, and Subjects Taking Oral Contraceptives”. Br. J. Anaesth. 1968; 40: 825
- Zaroslinski J. F., Keresztesgy S.-N., Mais R. F., Oester Y. T. “Effect of Temperature on the Binding of Salicylate by Human Serum Albumin,”. Biochem. Pharmacd. 1974; 23: 1767–1776
- Moskowitz B., Somani S. M., McDonald R. H. “Salicylate Interaction with Penicillin and Secobarbital Binding Sits on Human Serum Albumin.”. Clin. Toxicol. 1973; 6: 247
- Olsen G. D. “Methadone Binding to Human Plasma Proteins”. Clin. Pharmacol. Ther. 1973; 14: 338
- Howell A., Sutherland R., Rolinson G. N. “Effects of Protein Binding on Levels of Ampicillin and Cloxacillin in Synovial Fluid,”. Clin. Pharmacol. Ther. 1972; 13: 724–732
- Barza H. “Reversibility of Protein Binding of Penicillin: An in vitro Study Employing a Rapid Diafiltration Process,”. Antimicrob. Agents Chemother. 1972; 1: 427–432
- Rone A., Lunde P. K. M., Jalling B., Yaffe S. J., Sjoquist F. “Plasma Protein Binding of Diphenylhydantoin in Normal and Hyperbilirubinemic Infants,”. J. Pediatr. 1971; 78: 877–882
- Runkel R., Forchielli E., Sevelius H., Chaplin M., Segre E. “Non-linear Plasma Level Response to High Doses of Naproxen”. Clin. Pharmacol. Ther. 1974; 15: 261
- Hooper W. D., Bochner F., Eadie M. J., Tyrer J. H. “PIasma Protein Binding of Diphenylhydantoin, Effect of Sex Hormone, Renal and Hepatic Disease”. Clin. Pharmacol. Ther. 1974; 15: 276
- Hucker H. B., Stauffer S. C., White S. E. “Effect of Halofenate on Binding of Various Drugs to Human Plasma Proteins and on the Plasma Half-Life of Antipyrine in Monkey”. J. Pharm. Sci. 1972; 61: 1491
- Jun H. W., Luzzi L. A., Hsu P. L. “Phenylbutazone-Sodium Warfarin Binding Using a Fluorescent Probe Technique”. J. Pharm. Sci. 1972; 61: 1835
- Kostenbauder H. B., Jawad M. J., Perrin J. H., Averhast V. “Dialysis and Circular Dichroism Study of the Binding of Sulfaethidole to Crystalline and Fraction V BSA”. J. Pharm. Sci. 1971; 60: 1659
- Sutherland R., Croydon E. A. P., Rolinson G. N. “Flucloxacillin, a New Isoxazolyl Penicillin, Compared with Oxacillin, Cloxacillin, and Dicloxacillin,”. Br. rued. J. 1970; 4: 455–460
- Odarderlöf I.-C., Borga O. “Kinetics of Diphenylhydantoin in Uremia Patients, Consequence of Decreased Plasma Protein Binding,”. Eur. J. Clin. Pharmacol. 1974; 7: 31–37
- Jorgensen A., Hansen V., Fredricson Overo K. “The Distribution Pattern of a Series of Tricyclic and Bicyclic Thymoleptics Compared with Their Lipophilic Properties and Binding to Plasma Protein,”. Acta Pharmacol. Toxicol. 1973; 33: 81–91
- Rennick B. R. “Dopamine: Renal Tubular Transport in the Dog and Plasma Binding Studies”. Am. J. Physiol. 1968; 215: 532
- Ryan J. J., Parker C. W., Williams R. C. “γ-Globulin Binding of Morphine in Heroin Addicts”. J. Lab. Clin. Med. 1972; 80: 155
- Brock A. “Binding of Digoxin to Human Serum Proteins: Influence of pH on the Binding of Digoxin to Human Albumin,”. Acta Pharmacol. Toxicol. 1974; 34: 260–266
- Zaroslinski J. F., Mais R. F., Keresztesgy S.-N., Oester Y. T. “Temperature Dependence of Salicylic Acid Binding to Albumin as Studied by Frontal Gel Chromotography”. Fed. Proc. 1972; 31: 1714
- Baker S. P. “The Binding of Amphetamine and Related Compounds to Plasma Proteins”. J. Pharm. Pharmacol., Suppl. 1972; 24: 1648
- Baggot J. D. “Species Differences in Plasma Binding of Morphine and Codeine,”. Am. J. Vet. Res. 1973; 34: 571–574
- Doherty J. E. “Tritiated Digoxin, XV, Serum Protein Binding in Human Subjects,”. Am. J. Cardiol. 1971; 28: 326–330
- Skivington M. A. “Protein Binding of Three Tritiated Muscle Relaxants,”. Br. J. Anaesth. 1972; 44: 1030–1034
- Wilson A. G., Houston J. B., Bridger J. W. “The Binding of Aliphatic Carbamates to Bovine Serum Albumin,”. Biochem. J. 1972; 130: 85P
- Danon A. “Binding of Catecholamines to Human Serum Albumin”. J. kb. Clin. Med. 1971; 78: 810
- Rosen A. “The Measurement of Binding Constants Using Circular Dichroism Binding of Phenylbutazone and Oxyphenylbutazone,”. Biochem. Pharmacol. 1970; 19: 2075–2081
- McArthur J. N. “The Binding of Indomethacin, Salicylic Acid, and Phenobarbitone to Human Whole Blood in vitro,”. J. Pharm. Pharmacol. 1971; 23: 32–36
- Smart G. A., Brown S. S. “Preparative Ultracentrifugation of Small Samples of Plasma and the Protein Binding of Methaqualone”. Anal. Biochem. 1970; 35: 518
- Murakawa T., Wakai Y., Nishida M. “Studies on the Relationship of Protein Binding and Gel-Affinity of Antibiotics Including Penicillins”. J. Antibiot. 1970; 23: 481
- Garten S., Wosilait W. D. “Comparative Study of the Binding of Coumarin Anticoagulants and Serum Albumin,”. Biochem. Pharmacol. 1971; 20: 1661–1668
- May P., Sanders F. J., Donabediin R. K. “Binding of Catechol Derivatives to Human Serum Proteins”. Experientia 1974; 30: 304
- Miiller W., Wollert V. “Characterization of the Binding of Benzodiazepines to Human Serum Albumin,”. Naunyn-Schmiedeberg's Arch. Pharmacol. 1973; 280: 229–237
- Orme B. M., Culter R. E. “Protein Binding, Renal Clearance and Volume of Distribution of Kanamycin”. Clin. Res. 1969; 17: 130
- Kuschinsky K. “Protein Binding of Different Cardiac Glycosides, Determined by Means of the Sephadex Gel Filtration Method”. Naunyn-Schmiedeberg's Arch. Pharmakol. Exp. Pathol. 1968; 259: 394
- Krieglstein J., Lier F., Michaelis J. “Albumin Binding and Hydrophobic Character of Promazine and Chlorpromazine Metabolities,”. Naunyn-Schmiedeberg's Arch. Pharmacol. 1972; 272: 121–130
- Beeck R., Braun W. “The Effect of Some Drugs on the Protein Binding of Phenol Red and Digitoxin,”. Naunyn-Schmiedeberg's Arch. Pharmacol. 1972; 275: 277–287
- Krieglstein J., Kusehinsky G. “The Interaction of Phenothiazine Derivatives with Bovin Serum Albumin,”. Naunyn-Schmiedeberg's Arch. Pharmacol. 1969; 262: 1–16
- Kuschinsky K. “On the Characteristics of the Binding of Cardiac Glycosides by Plasma Proteins,”. Naunyn-Schmiedeberg's Arch. Pharmakol. Exp. Pathol. 1969; 262: 388–398
- Jälhnchen E., Krieghein J., Kuschinsky G. “The Significance of the Benzene Rings in Protein Binding of Promazine and Chlorpromazine,”. Naunyn-Schmiedeberg's Arch. Pharmakol. Exp. Pathol. 1969; 263: 375–386
- Glas Per H., Krieglstein J. “The Protein Binding of Some Psychoactive Drugs with a Tricyclic Ring System in Relation to Their Chemical Constituents,”. Naunyn-Schmiedeberg's Arch. Pharmakol. 1970; 265: 321–334
- Kurz H. “Differentiation between Drug-Binding Plasma Proteins”. Naunyn-Schmiedeberg's Arch. Pharmakol. 1971; 269: 426
- Parke D. V., Lindup W. E. “Quantitative and Qualitative Aspects of the Plasma Protein Binding of Carbenoxrolone, an Ulcer-Healing Drug”. Ann. N. Y. Acad. Sci. 1973; 226: 200
- Dromgoole S. H. “The Binding Capacity of Albumin and Renal Disease,”. J. Pharmacol. Exp. Ther. 1974; 191: 318–323
- Prandota J., Pruitt A. W. “Furosemide Binding to Human Albumin and Plasma of Nephrotic Children,”. Clin. Pharmacol. Ther. 1975; 17: 159–166
- Olsen G. P. “Morphine Binding to Human Plasma Protein,”. Clin. Pharmacol. Ther. 1975; 17: 31–35
- Porvis G. “The Binding of Catecholamines to Human Serum Protein,”. Biochem. Pharmacol. 1975; 24: 707–712
- Mather L. E., Tucker G. T., Pflug A. E., Lindop M. J., Wilkinson G. “Meperidine Kinetics in Man: Intravenous Injection in Surgical Patients and Volunteers,”. Clin. Pharmacol. Ther. 1975; 17: 21–30
- Hadjian A. J., Chedin M., Cochet C., Chambay E. M. “Cortisol Binding to Protein in Plasma in the Human Neonate and Infant,”. Pediatr. Res. 1975; 9: 40–45
- Boman G., Ringberger V. A. “Binding of Rifampicin by Human Plasma Protein,”. Eur. J. Clin. Pharmacol. 1974; 7: 369–373
- Boman G. “Protein Binding of Rifampicin: A Review,”. Scand. J. Resp. Dis., Suppl. 1973; 84: 40–43
- Aoyagi T. “Protein Binding of Rifampicin to Different Individual Sera,”. Scand. J. Resp. Dis., Suppl. 1973; 84: 44–49
- Chiou W. L., Hsiao J.-H. “A New Single Approach to Study the Protein Binding of Volatile and Gaseous Compounds. I. Propellants, Halothane and Cyclopropane. Res. Commun. Chem. Pathol. Pharmacol. 1974; 8: 273–287
- Chien Y. W., Lambert H. J., Karini A. “Comparative Binding of Disopyramide Phosphate and Quinidine Sulfate to Human Plasma Protein,”. J. Pharm. Sci. 1974; 63: 1877–1879
- Appelgren C., Borg K. O., Elofsson R., Johansson K. A. “Binding of Adrenergic Beta-Receptor Antagonists to Human Serum Albumin,”. Acta Pharm. Suec. 1974; 11: 325–332
- Johansson K. A., Appelgren C., Borg K. O., Elofsson R. “Binding of Two Adrenergic Beta-Receptor Antagonists, Alprenolol and H 93/96 to Human Serum Protein,”. Acta Pharm. Suec. 1974; 11: 333–346
- Nilsson B., Agren A. “Complex Formation between Macromolecules and Drugs X,”. Acta Pharm. Suec. 1974; 11: 391–400
- Wendorferjun A., Kuenzes W., Urbanek R. “The Influence of Age on the Activity of Acetylsalicylic Acid-Esterase and Protein-Salicylate Binding,”. EUP. J. Clin. Pharmacol. 1974; 7: 227–231
- Prandota J., Pruitt A. W. “Binding of C14-Furosemide to Human Albumin and Plasma of Nephrotic Children”. Pharmacologist 1974; 16: 220
- Corrocher R., DeSandre G., Pacor M. L., Hoffbrand A. V. “Hepatic Protein Binding of Folate,”. Clin. Sci. Mol. Med. 1974; 46: 551–554
- Wedman M., Agurell S., Ehrnebo M., Jones G. “Binding of (+)- and (−).Δ′-Tetrahydrocannabinofs and (-)-7-hydroxy-Δ′-TetrahydrocannabinoI to Blood Cells and Plasma Proteins in Man,”. J. Pharm. Pharmacol. 1974; 26: 914–916
- Klausner H. A., Wilcox H. G., Dingell J. V. “Studies on the Interaction of Δ9-Tetrahydrocannabinol with Plasma Lipoprotein,”. Acta Pharm. Suec. 1971; 8: 705–706
- Widman M., Nilsson I. M., Nibn J. L. G., Agurell S., Borg H., Grand-Strand B. “Plasma Protein Binding of 7-hydroxy-Δ′-Tetrahydrocannabinol: An Active Δ′ Tetrahydrocannabinol Metabolite,”. J. Pharm. Pharmacol. 1973; 25: 455–457
- Wahlqvist M., Nibn I. M., Sandberg F., Agrwll S. “Binding of Δ′-Tetrahydrocannabinol to Human Plasma Protein,”. Biochem. Pharmacol. 1970; 19: 2579–2584
- Shak V. P., Wallace S. M., Riegelman S. “Microultrafiltration Technique for Drug-Protein Binding Determination in Plasma,”. J. Phon. Sci. 1974; 63: 1364–1367
- Gazzard B. G., Ford-Hutchinson A. W., Smith M. J. H., Williams R. “The Binding of Paracetamol to Plasma Proteins of Man and Pig,”. J. Ph. Pharmacol. 1973; 25: 964–967
- Jacobsen J., Thiesen H., Brodersen R. “Effect of Fatty Acids on the Binding of Bilirubin to Albumin. Biochem. J. 1971; 126: 7p
- Chan G., Schiff D., Stern L. “Competitive Binding of Free Fatty Acids and Bilirubin to Albumin: Difference in HABA Dye Versus Sephadex G-25 Interpretation of Results,”. Clin. Biochem. 1971; 4: 208–214
- Spector A. A., Imig B. “Effect of Free Fatty Acid Concentration on the Transport and Utilization of Other Albumin-Bound Compounds: Hydroxyphenylazobenzoic Acid,”. Mol. Pharmacol. 1971; 7: 511–518
- Lipsett D., Madras B. K., Wurtan R. J., Munro H. N. “Serum Tryptophan Level after Carbohydrate Ingestion: Selective Decline in Non-Albumin Bound Tryptophan Concentration with Reduction in Serum Free Fatty Acid,”. Life Sci. 1973; 12: 57–64
- Fredholm B. B., Rane A., Person B. “Diphenylhydantoin Binding to Roteins in Plasma and Its Dependence on Free Fatty Acids and Bilirubin Concentration in Dog and Newborn Infants.,”. Pediatr. Res. 1975; 9: 26–30
- Knerwald J., Bizzi A., Garattini S. “Relationship between Lipolysis and Storage of Phenobarbital in Adipose Tissue,”. Eur. J. Pharmacol. 1972; 17: 186–188
- Kneiwald J., Bizzi A., Garattini S. “Relationship between Lipolysis and Storage of Diphenylhydantoin in Adipose Tissue,”. Experientia 1972; 28: 628–629
- Gugler R., Shoeman D. W., Azamoff D. L. “Effect of in vivo Elevation of Free Fatty Acids on Rotein Binding of Drugs,”. Pharmacology 1974; 12: 160–165
- Witiak D. T., Whitehouse M. W. “Species Difference in the Albumin Binding of 2,4,6-Trinitrobezaldehyde, Chlorophenoxyacetic Acid, 2-(4′-hydroxyben-zeneazo) Benzoic Acid and Some Other Acid Drugs–-The Unique Behavior of Rat Plasma Albumin,”. Biochem. Pharmacol. 1969; 18: 971–977
- Far R. S., Reid R. T., Minden P. “Spontaneous and Induced Alteration in the Anion Binding Properties of Human Albumin”. J. Clin. Invest. 1966; 45: 1006
- Puche R. C., Morisoli L. S. “Role of Serum Albumin in the Transport and Storage of Dehydro-epiandrosterone Sulfate,”. Eur. J. Steroid 1967; 2: 193–204
- Denko C. W., Purser D. B., Johnson R. M. “Amino Acid Composition of Serum Albumin in Normal Individuals and in Patients with Neumatoid Arthritis,”. Clin. Chem. 1970; 16: 54–57
- Thorp J. M. “Inter and Intra Species Differences in the Binding Anionic Compounds to Albumin,”. Exerpta Med. Int. Congr. Ser. 1972; 254: 98–109
- Lasser E. C., Fan R. S., Fujimagari T., Tripp W. N. “The Significances of Protein Binding of Contrast Media in Roentgen Diagnosis,”. Am. J. Roentgenol., Radium Ther. Nucl. Med. 1962; 87: 338–365
- Chignell C. F., Starkweather D. K. “Optical Studies of Drug-Protein Complexes V,” The Interaction of Phenylbutazone, Flufenamic Acid and Dicoumarol with Acetylsalicylic Acid-Treated Serum Albumin,”. Mol. Pharmacol 1971; 7: 229–237
- Hawkins D., Pinekard R. N., Farr R. S. “Acetylation of Human Serum Albumin by Acetylsalicylic Acid,”. Science 1968; 160: 780–781
- Hawkins D., Pinckard R. N., Crawford I. P., Farr R. S. “Structural Changes in Human Serum Albumin Induced by Ingestion of Acetylsalicylic Acid”. J. Clin. Invest. 1969; 48: 536
- Sudlow G., Birkett D. J., Wade D. N. “Spectroscopic Techniques in the Study of Protein Binding: The Use of 1-Anilino-8-naphthalenesulphonate as a Fluorescent Probe for the Study of the Binding of Iophenoxic and Iopanoic Acids to Human Serum Albumin,”. Mol. Pharmacol. 1973; 9: 649–657
- Markus G., Karush F. “Structural Effects of Anionic Azo Dyes on Serum Albumin,”. J. Am. Chem. Soc. 1958; 80: 89–94
- Klotz I. M., Roger G. P., Sloniewsky A. R. “Macromolecular-Small Molecule Interaction. Strong Binding and Cooperativity in a Model Synthetic Polymer,”. Biochemistry 1969; 8: 4752–4756
- Tsukui T., Takasu N., Onaya T., Yamada T. “Effect of Nonsteroidal Anti-inflammatory Drugs on Plasma Protein-Thyroxine Interaction,”. Roc. Soc. Exp. Biot. Med. 1974; 146: 494–498
- Peters J. H., Gordon G. R., Biggs J. T., Levy L. “The Disposition of Dapsone and Monoacetyldapsone in the Dog,”. Roc. Soc. Exp. Biot. Med. 1975; 148: 251–255
- Riley R. W., Levy L. “Characteristics of the Binding of Dapsone and Monoacetyldapsone by Serum Albumin,”. Roc. Soc. Exp. Biot. Med. 1973; 142: 1168–1178
- Wingard L. B., Oie S., Levy G. “Effect of Bilirubin on the Distribution, Elimination and Anticoagulant Action of Dicumarol in Gunn Rats,”. Roc. Soc. Exp. Biot. Med. 1975; 148: 397–401
- Aggeler P. M., O'Reilly R. A., Leong L., Kowitz P. A. “Potentiation of Anticoagulant Effect of Warfarin by Phenylbutazone,”. N. Engl. J. Med. 1967; 276: 496–501
- Eisen M. J. “Combined Effect of Sodium Warfarin and Phenylbutazone,”. J. Am. Med. Assoc. 1964; 189: 64–65
- O'Reilly R. A., Aggeler P. M. “Phenylbutazone Potentiation of Anticoagulant Effect: Fluorometric Assay of Warfarin,”. Proc. Soc. Exp. Biol. Med. 1968; 128: 1080–1081
- Solomon H. M., Schrogie J. J. “The Effect of Various Drugs on the Binding of Warfarin-C14 to Human Albumin,”. Biochem. Pharmacol. 1967; 16: 1219–1226
- Solomon H. M., Schrogie J. J., Williams D. “The Displacement of Phenyl-butazone-C14 and Warfarin from Human Albumin by Various Drugs and Fatty Acids,”. Biochem. Pharmacol. 1968; 17: 143–151
- Jähnchen E., Wingard L. B., Levy C. “Effect of Phenylbutazone OR the Distribution, Elimination and Anticoagulant Action of Dicumarol in Rats,”. J. Pharmacol. Exp. Ther. 1973; 187: 176–184
- Shen D., Gibaldi M. “Critical Evaluation of Use of Effective Protein Fractions in Developing Pharmacokinetic Models for Drug Distribution,”. J. Pharm. Sci. 1974; 63: 1698–1702
- Azzollini F., Gauaniga A., Lodola E., Natangelo R. “Elimination of Chloramphenicol and Thiamphenicol in Subjects with Cirrhosis of the Liver,”. Int. J. Clin. Pharmacol., Ther. Toxicol. 1972; 6: 130–134
- Levi A. J., Sheriock S., Walker D. “Phenylbutazone and Isoniazed Metabolism in Patients with Liver Disease in Relation to Previous Drug Therapy,”. Lancet 1968; 1: 1275–1279
- Clarenburg R., Barnhort J. L. “Interaction of Serum Albumin and Bilirubin at Low Concentration,”. Am. J. Physiol. 1973; 225: 493–496
- Kapitulnik J., Blondheim S. H., Kaufmann N. A. “Sephadex Adsorption of Bilirubin from Neonatal and Adult Serum”. Clin. Chem. 1972; 18: 4347
- Tuilie M., Lardenos R. “The Binding of Unconjugated Bilirubin by Human Sera and Purified Albumin,”. Biol. Neonat. 1972; 21: 447–462
- Oie S. “Pharmacokinetic Implications of Bilirubin Displacement,”. Presented at the State University of New York at Buffalo. 1974
- Levi K. J., Gatmaitan Z., Arias I. M. “Two Hepatic Cytoplasmic Protein Fractions, Y and Z, and Their Possible Role in the Hepatic Uptake of Bilirubin, Sulfobromophthalein and other Anions”. Clin. Invest. 1969; 48: 2156
- Davis D. R., Yeary R. A. “Bilirubin Binding to Hepatic Y and 2 Protein (Ligandin): Tissue Bilirubin Concentration in Phenobarbital Treated Gunn Rat,”. Roc. Soc. Exp. Biol. Med. 1975; 148: 9–13
- Bloomer J. R., Berk P. D., Vergalla J., Berlin N. I. “Influence of Albumin on the Hepatic Uptake of Unconjugated Bilirubin,”. Clin. Sci. Mol. Med. 1973; 45: 505–516
- Bloomer J. R., Berk P. D., Vergalla J., Berlin N. I. “Influence of Albumin on the Extravascular Distribution of Unconjugated Bilirubin,”. Clin. Sci. Mol. Med. 1973; 45: 517–526
- Reyes H., Levi A. J., Gatmaitan Z. “Studies of Y and Z, Two Hepatic Cytoplasmic Organic Anion-Binding Proteins: Effect of Drugs, Chemicals, Hormones and Cholestasis,”. Clin. Invest. 1971; 50: 2242–2252
- Yaffe S. J., Levy G., Matsuzawa T., Baliah T. “Enhancement of Glucuronide Conjugation Capacity in a Hyperbilirubinemic Infant Due to Apparent Enzyme Induction by Phenobarbital,”. N. Engl. J. Med. 1966; 275: 1461–1465
- Silverman W. A., Andersen D. H., Blane W. A., Crozier D. N. “A Difference in Mortality Rate and Incidence of Kericterus among Premature Infants Allotted to Two Prophylactic Antibacterial Regimens,”. Pediatrics 1956; 18: 614–625
- Odell G. B. “Influence of Binding on the Toxicity of Bilirubin,”. Ann. N. Y. Acad Sci. 1974; 226: 224–237
- Ryan J. J., Parker C. W., Williams R. C. “γ-Globulin Binding of Morphine in Heroin Addicts,”. J. Lab. Clin. Med. 1972; 80: 155–164
- Butler V. P., Watson J. F., Schmidt D. H., Gardner J. D., Mandel W. J., Skelton C. L. “Reversal of the Pharmacological and Toxic Effects of Cardiac Glycosides by Specific Antibodies,”. Pharmacol. Rev. 1973; 25: 239–248
- Schmidt D. H., Butler V. P. “Immunological Protection Against Digoxin Toxicity,”. J. Clin. Invest. 1971; 50: 866–871
- Schmidt D. H., Butler V. P. “Reversal of Digoxin Toxicity with Specific Antibodies,”. J. Clin. Invest. 1971; 50: 1738–1744
- Schmidt D. H., Mecker C., Kaiser G. A., Beach P. M., Butler V. P. “The Effect of Digoxin-Specific Antibodies on the Distribution of Digoxin-3 H in Dog,”. Circulation Suppl. 1971; 44(II)116
- Tillement J. P., Zini R., d'Athir P., Vassent G. “Binding of Certain Acidic Drugs to Human Albumin: Theoretical and Practical Estimation of Fundamental Parameters,”. Eur. J. Clin. Pharmacol. 1974; 7: 307–313
- MIMED, State University of New York at Buffalo. Office of Computer Services Adaptation of MMIC. A Digital Simulation Language. Control Data Corp., St Paul, Minnesota 1968